We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Marie Gerval, MBBS
07734386042
m.gerval@imperial.ac.uk
John Stevenson, MBBS
0207 351 8112
j.stevenson@imperial.ac.uk
Thrombosis Venous Thrombosis Insulin Resistance
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Ultra-low-dose oral E2/D will have more beneficial effects than trans-dermal HRT on lipids and insulin resistance in postmenopausal women, whilst adverse effects on coagulation will be avoided.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
You can take part if:
You may not be able to take part if:
This is in the inclusion criteria above
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Marie Gerval, MBBS
07734386042
m.gerval@imperial.ac.uk
John Stevenson, MBBS
0207 351 8112
j.stevenson@imperial.ac.uk
The study is sponsored by Royal Brompton & Harefield NHS Foundation Trust and is in collaboration with Chelsea and Westminster NHS Foundation Trust; Imperial College Healthcare NHS Trust.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
